Urologie pro praxi 2/2026
Drug interactions in the therapy of bladder cancer
The rapid development of oncological therapies is accompanied by an increasing incidence of drug interactions, which can significantly affect both the safety and efficacy of treatment. Most oncology patients suffer from additional chronic conditions, and due to age and comorbidities, this often leads to polypharmacy. As a result, the risk of interactions increases not only between prescribed medications, but also with over-the-counter products, dietary supplements, herbal preparations, or certain foods. Drug interactions in oncology may be both pharmacokinetic and pharmacodynamic, and can manifest as reduced therapeutic efficacy or an increased risk of toxicity. Timely identification of potential interactions is essential for optimizing treatment and minimizing risks, particularly in oncology patients. A clinical pharmacist or clinical pharmacologist can make a significant contribution to the proper evaluation and interpretation of drug interactions in individual patients.
Keywords: drug interaction, bladder cancer, inhibitor, inducer, clinical pharmacy.